[go: up one dir, main page]

CN116794325B - 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用 - Google Patents

敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用 Download PDF

Info

Publication number
CN116794325B
CN116794325B CN202310711086.8A CN202310711086A CN116794325B CN 116794325 B CN116794325 B CN 116794325B CN 202310711086 A CN202310711086 A CN 202310711086A CN 116794325 B CN116794325 B CN 116794325B
Authority
CN
China
Prior art keywords
ampk
slc35f6
alpp
activity
knocking down
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310711086.8A
Other languages
English (en)
Other versions
CN116794325A (zh
Inventor
松阳洲
朱建熹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Priority to CN202310711086.8A priority Critical patent/CN116794325B/zh
Priority to PCT/CN2023/108489 priority patent/WO2024254941A1/zh
Publication of CN116794325A publication Critical patent/CN116794325A/zh
Application granted granted Critical
Publication of CN116794325B publication Critical patent/CN116794325B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)

Abstract

本发明公开了敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用，涉及生物技术领域。本申请发明人研究发现，SLC35F6能够作为AMPK活性调控的新靶点，并通过进一步研究发现，SLC35F6‑ALPP复合体抑制AMPK的活性。本发明发现，敲低SLC35F6或ALPP能够激活AMPK，以SLC35F6或ALPP为目标，选取合适的siRNA，高效敲低SLC35F6或ALPP，为AMPK的激活提供新的技术方案。本发明首次明确了SLC35F6对AMPK活性调控作用，为与AMPK活性相关的疾病的诊断和治疗提供新的防治药物研发途径和药物作用靶点，具有十分重要的药用价值。

Description

敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用
技术领域
本发明涉及生物技术领域，具体涉及敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用。
背景技术
AMPK(Adenosine 5‘-monophosphate(AMP)-activated protein kinase)即AMP依赖的蛋白激酶，是生物能量代谢调节的关键分子，广泛存在在动物和植物细胞中的蛋白质分子，是研究糖尿病及其他代谢相关疾病的核心。它表达于各种代谢相关的器官中，能被机体各种刺激激活，包括细胞压力、运动和很多激素及能影响细胞代谢的物质。AMPK作为一种营养和能量传感器，它可以感知细胞内ATP的水平高低。当线粒体被抑制，低能量供应条件下，AMPK磷酸化特异性的酶和位点，增加ATP生成，降低ATP消耗，以此来恢复能量平衡。
AMPK是代谢调节中最重要的激酶，当细胞内能量缺乏时，AMPK被上游激酶磷酸化激活，进而磷酸化许多代谢中的关键酶以及控制蛋白，促进分解代谢，抑制合成代谢，增加ATP的积累，为细胞提供能量。传统观点认为，AMPK的激活是由于细胞内AMP的浓度上升，与AMPK的γ亚基结合，改变AMPK异源三聚体的构象，使其α亚基的T172位点能够被上游激酶LKB1磷酸化，进而激活AMPK全酶。近年来的研究发现，AMPK的激活在不同的亚细胞区域并不一致，AMPK能够在溶酶体上激活，其溶酶体定位依赖于AMPKβ亚基的第二位甘氨酸的豆蔻酰化修饰。另外，除了响应AMP，溶酶体上的AMPK还能响应糖代谢次级产物FBP(果糖-1,6-二磷酸)的浓度变化。溶酶体上调控AMPK活性的蛋白，以及这些蛋白是否能够作为潜在的药物靶点，影响AMPK的活性，现在还不得而知。
现有的AMPK激活剂基于的调控机制主要集中在增加AMPKα的磷酸化，所涉及的调控位点已经饱和。目前还没有针对AMPK去磷酸化的机制，去探索和发现AMPK抑制剂和激活剂。
发明内容
本发明的目的在于克服现有技术的不足，提供敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用。
为实现上述目的，本发明采取的技术方案为：SLC35F6在制备AMPK活性抑制剂中的应用。本申请的目的在于探索AMPK的溶酶体激活机制，进而发现新的AMPK活性调控蛋白。研究显示，溶酶体上的AMPK在能够感受糖代谢次级产物的变化，不同于整个细胞中的AMPK活性调控。所以，溶酶体上应该存在新的AMPK调节蛋白，能够更加直接的调控AMPK活性。本发明利用BiFC和临近标记技术，发现了SLC35F6-ALPP复合体在溶酶体上抑制AMPK的活性，而SLC35F6的配体UDP-GlcNAc能够解除SLC35F6-ALPP复合体对AMPK的抑制，进而激活AMPK，发挥疗效。
本发明还提供敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用。
作为本发明所述应用的优选实施方式，所述试剂包括敲低SLC35F6基因表达的siRNA。
作为本发明所述应用的优选实施方式，所述siRNA的核苷酸序列如SEQ ID NO.1～SEQ ID NO.3任一项所示。
本发明还提供敲低或抑制ALPP的试剂在制备激活AMPK的药物中的应用。
作为本发明所述应用的优选实施方式，所述试剂包括敲低ALPP基因表达的siRNA。
作为本发明所述应用的优选实施方式，所述siRNA的核苷酸序列如SEQ ID NO.4～SEQ ID NO.6任一项所示。
本发明还提供一种AMPK激活剂，所述激活剂包括敲低SLC35F6或ALPP中至少一种的试剂。
本发明还提供敲低SLC35F6或ALPP中至少一种的试剂在制备预防和/或治疗肿瘤、炎症或糖尿病的产品中的应用。
作为本发明所述应用的优选实施方式，所述试剂包括UDP-GlcNAc。
本发明的有益效果：本发明提供敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用。本申请发明人研究发现，SLC35F6能够作为AMPK活性调控的新靶点，并通过进一步研究发现，SLC35F6-ALPP复合体在溶酶体上抑制AMPK的活性。本发明发现，敲低SLC35F6或ALPP能够激活AMPK，以SLC35F6或ALPP为目标，选取合适的siRNA，高效敲低SLC35F6或ALPP，为AMPK的激活提供新的技术方案。本发明首次明确了SLC35F6对AMPK活性调控作用，为与AMPK活性相关的疾病的诊断和治疗提供新的防治药物研发途径和药物作用靶点，具有十分重要的药用价值。
附图说明
图1为实施例1敲低SLC35F6后p-AMPK，AMPK，SLC35F6，tubulin的表达结果图；
图2为实施例2敲低ALPP后p-AMPK，AMPK，p-ACC1，ACC1，ALPP，tubulin的表达结果图；
图3为实施例3细胞裂解液和免疫沉淀后beads中GST，p-AMPK，AMPK，tubulin的表达结果图；
图4为实施例4敲低SLC35F6和饥饿处理后的p-AMPK，AMPK，p-ACC1，ACC1，SLC35F6，tubulin的表达结果图；
图5为实施例4敲低SLC35F6和H2O2处理后的p-AMPK，AMPK，p-ACC1，ACC1，SLC35F6，tubulin的表达结果图；
图6为实施例4敲低SLC35F6和AICAR处理后的p-AMPK，AMPK，p-ACC1，ACC1，SLC35F6，tubulin的表达结果图。
具体实施方式
以下通过实施例形式的具体实施方式，对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
实施例1
本实施例通过实验验证敲低SLC35F6对AMPK活性的影响，具体实验步骤如下：
(1)将生长状态良好的HEK293T细胞加入六孔板中，于37℃，5％CO2培养；(2)将终浓度为100nM对照siRNA(由广州锐博生物提供,货号
#siN0000001-1-5)、100nM用于敲低SLC35F6的实验组siRNA分别与10ul的RNAimax试剂、200ul的optimen混匀，得混合液；所述实验组siRNA的序列分别为：
实验组一(#1)：5′-GCAUGGUGUUGGACAGCUU-3′；
实验组二(#2)：5′-GCAUUGCCUUCUUCAACUU-3′；
实验组三(#3)：5′-GAGGAGAAGUUCGUCUACA-3′。
(3)将混合液室温静置20min后，加入六孔板的HEK293T细胞中，6小时后更换新鲜培养基；48h后，收集并裂解细胞，1000gx10min离心，收集上清，并提取蛋白。
(4)免疫印迹检测：将步骤(3)得到的蛋白进行聚丙烯酰胺凝胶电泳，电泳参数为：恒压80V，20min加上120v，45min，然后恒流0.2A，1h转膜，5％脱脂牛奶封闭1h；用一抗p-AMPK，AMPK，SLC35F6，tubulin孵育过夜，第二天再敷育对应的二抗，检测相应蛋白的表达水平。
实验结果如图1所示。p-AMPK(T172)表明AMKP的磷酸化程度，代表AMPK的活性。由图1可知看出，实验组没有表达SLC35F6，说明实验组成功敲低SLC35F6；对照组的p-AMPK的表达低于实验组，说明敲低SLC35F6后AMPK被激活。
实施例2
本实施例通过实验验证敲低ALPP对AMPK活性的影响，具体实验步骤如下：
(1)将生长状态良好的HEK293T细胞加入六孔板中，于37℃，5％CO2培养；
(2)将终浓度为100nM对照siRNA、100nM用于敲低ALPP的实验组siRNA分别与10ul的RNAimax试剂、200ul的optimen混匀，得混合液；所述实验组siRNA的序列分别为：
实验组一(#1)：5′-CUACGCAGCUCAUCUCCAA-3′；
实验组二(#2)：5′-CUGGAGACAUGAAAUACGA-3′；
实验组三(#3)：5′-CGGUCCUCCUAUACGGAAA-3′。
(3)将混合液室温静置20min后，加入六孔板的HEK293T细胞中，6小时后更换新鲜培养基；48h后，收集并裂解细胞，1000gx10min离心，收集上清，并提取蛋白。
(4)免疫印迹检测：将步骤(3)得到的蛋白进行聚丙烯酰胺凝胶电泳，电泳参数为：恒压80V，20min加上120v，45min，然后恒流0.2A，1h转膜，5％脱脂牛奶封闭1h；用一抗p-AMPK，AMPK，p-ACC1，ACC1，ALPP，tubulin孵育过夜，第二天再敷育对应的二抗，检测相应蛋白的表达水平。
实验结果如图2所示。由图2可知看出，实验组没有表达ALPP，说明实验组成功敲低ALPP；对照组的p-AMPK的表达低于实验组，说明敲低ALPP后AMPK被激活。
实施例3
本实施例通过实验验证降低SLC35F6和ALPP的相互作用对AMPK活性的影响，具体实验步骤如下：
(1)将生长状态良好的HEK293T细胞加入六孔板中，于37℃，5％CO2培养；采用PEI将Flag-SLC35F6和GST-ALPP顺转入HEK293T细胞，6小时后换液；
(2)48h后，裂解细胞，在细胞裂解液中加入UDP-GlcNAc孵育1h；
(3)2h后在裂解液中加入GST beads，旋转孵育2小时；
(4)beads沉淀后，用裂解液洗涤三次；
(5)采用免疫印迹检测细胞系裂解液和免疫沉淀后beads中GST，p-AMPK，AMPK，tubulin的水平。
实验结果如图3所示。Flag和GST代表过表达的Flag-SLC35F6和GST-ALPP。5％input组里面，代表总的含量，IP组里面，代表免疫共沉淀下拉下来的成分，IP/Input的比值越高，代表相互结合越强。由图3可知，相比于Veh的对照组(仅含有1XPBS)，UDP-GlcNAc的加入使得p-AMPK增加，表明UDP-GlcNAc能够提升AMPK的活性(对比第二泳道和第三泳道)。同时，UDP-GlcNAc能够降低GST磁珠免疫沉淀GST-ALPP过后的Flag-SLC35F6，表明UDP-GlcNAc能够降低GST-ALPP和Flag-SLC35F6的相互作用。综上，UDP-GlcNAc能够通过降低SLC35F6和ALPP的相互作用，进而提升AMPK的活性。
实施例4
本实施例验证敲低SLC35F6联合常规AMPK激活剂对AMPK活性的影响，具体实验步骤如下：
(1)将生长状态良好的HEK293T细胞加入六孔板中，于37℃，5％CO2培养；
(2)将终浓度为100nM对照siRNA、100mM用于敲低SLC35F6的实验组siRNA分别与10ul的RNAimax试剂、200ul的optimen混匀，得混合液；
(3)将混合液室温静置20min后，加入六孔板的HEK293T细胞中，6小时后更换新鲜培养基；
(4)48h后，分别进行饥饿处理：使用无葡萄糖培养基代替正常培养基16h、双氧水处理：正常培养的细胞中加入浓度为1mM的H2O2,5min、AICAR处理：正常培养的细胞中加入AMPK激活剂2mM AICAR 4h；
(5)收集并裂解细胞，1000gx10min离心，收集上清，并提取蛋白；
(6)将蛋白进行免疫印迹检测：聚丙烯酰胺凝胶电泳，电泳参数：恒压80V，20min加上120v，45min，然后恒流0.2A，1h转膜，5％脱脂牛奶封闭1h；用一抗p-AMPK，AMPK，p-ACC1，ACC1，SLC35F6，tubulin孵育过夜，第二天再敷育对应的二抗，检测相应蛋白的表达水平。
结果如图4～6所示。由图4～6可知，采用常规AMPK激活剂(如葡萄糖饥饿16小时，双氧水处理5分钟，AMP类似物AICAR处理4小时)都能够提升AMPK的磷酸化(对比第一泳道和第二泳道)。敲低SLC35F6联合常规AMPK激活剂，能在本来已经激活的AMPK基础上更近一步激活(对比第二泳道和第四泳道)，由此表明敲低SLC35F6与常规AMPK激活剂联用能够更好的提升AMPK的活性。
最后应当说明的是，以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制，尽管参照较佳实施例对本发明作了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的实质和范围。

Claims (2)

1.敲低SLC35F6的试剂在制备激活AMPK的药物中的应用；所述试剂包括敲低SLC35F6基因表达的siRNA；所述siRNA的核苷酸序列如SEQ ID NO.1~SEQ ID NO.3任一项所示。
2.敲低ALPP的试剂在制备激活AMPK的药物中的应用；所述试剂包括敲低ALPP基因表达的siRNA；所述siRNA的核苷酸序列如SEQ ID NO.4~SEQ ID NO.6任一项所示。
CN202310711086.8A 2023-06-15 2023-06-15 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用 Active CN116794325B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202310711086.8A CN116794325B (zh) 2023-06-15 2023-06-15 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用
PCT/CN2023/108489 WO2024254941A1 (zh) 2023-06-15 2023-07-20 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310711086.8A CN116794325B (zh) 2023-06-15 2023-06-15 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Publications (2)

Publication Number Publication Date
CN116794325A CN116794325A (zh) 2023-09-22
CN116794325B true CN116794325B (zh) 2024-05-10

Family

ID=88039073

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310711086.8A Active CN116794325B (zh) 2023-06-15 2023-06-15 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Country Status (2)

Country Link
CN (1) CN116794325B (zh)
WO (1) WO2024254941A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116794325B (zh) * 2023-06-15 2024-05-10 中山大学 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050058530A (ko) * 2003-12-12 2005-06-17 주식회사 엠디바이오알파 5' 에이엠피-활성화 단백질 인산화 효소 활성 증진 물질의스크리닝 방법
KR20120051173A (ko) * 2010-11-12 2012-05-22 경희대학교 산학협력단 Ａｍｐｋ 활성화제
AU2014200497A1 (en) * 2007-01-16 2014-02-20 Ipintl, Llc Novel Composition for Treating Metabolic Syndrome
CA2875418A1 (en) * 2013-12-17 2015-06-17 Agada Biosciences, LLC Method and agents to quantify proteins from tissues
WO2017052340A1 (ko) * 2015-09-25 2017-03-30 고려대학교 산학협력단 운동유사효과 유도용 약학 조성물
WO2018090851A1 (zh) * 2016-11-21 2018-05-24 厦门大学 FBP aldolase在制备激活AMPK的药物中的用途
KR20180104492A (ko) * 2017-03-13 2018-09-21 연세대학교 산학협력단 카월을 유효성분으로 포함하는 ampk 활성 조절용 조성물
CN111346229A (zh) * 2019-05-17 2020-06-30 中山大学 端粒结合蛋白hp1bp3在制备肿瘤细胞调控剂中的应用
CN115869339A (zh) * 2022-10-31 2023-03-31 中山大学附属第一医院 铜螯合剂与ampk激活剂联合用于制备肿瘤治疗药物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090182134A1 (en) * 2002-11-14 2009-07-16 Dharmacon, Inc. siRNA targeting phosphatases
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
EP2262541A4 (en) * 2008-03-12 2012-02-29 Oncotherapy Science Inc C2ORF18 AS DESTINATIONS FOR CANCER THERAPY AND DIAGNOSIS
EP3060650A4 (en) * 2013-10-25 2017-04-19 Agency For Science, Technology And Research Culturing pluripotent stem cells
KR101925020B1 (ko) * 2017-04-21 2018-12-04 연세대학교 산학협력단 Mkrn1의 발현 또는 활성 억제제를 유효성분으로 함유하는, 대사성 질환의 예방 및 치료용 약학적 조성물
KR20220087022A (ko) * 2020-12-17 2022-06-24 주식회사 초메디신 뇌종양 진단 또는 예후 예측용 용질 운반체 바이오마커 조성물
CN116794325B (zh) * 2023-06-15 2024-05-10 中山大学 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050058530A (ko) * 2003-12-12 2005-06-17 주식회사 엠디바이오알파 5' 에이엠피-활성화 단백질 인산화 효소 활성 증진 물질의스크리닝 방법
AU2014200497A1 (en) * 2007-01-16 2014-02-20 Ipintl, Llc Novel Composition for Treating Metabolic Syndrome
KR20120051173A (ko) * 2010-11-12 2012-05-22 경희대학교 산학협력단 Ａｍｐｋ 활성화제
CA2875418A1 (en) * 2013-12-17 2015-06-17 Agada Biosciences, LLC Method and agents to quantify proteins from tissues
WO2017052340A1 (ko) * 2015-09-25 2017-03-30 고려대학교 산학협력단 운동유사효과 유도용 약학 조성물
WO2018090851A1 (zh) * 2016-11-21 2018-05-24 厦门大学 FBP aldolase在制备激活AMPK的药物中的用途
KR20180104492A (ko) * 2017-03-13 2018-09-21 연세대학교 산학협력단 카월을 유효성분으로 포함하는 ampk 활성 조절용 조성물
CN111346229A (zh) * 2019-05-17 2020-06-30 中山大学 端粒结合蛋白hp1bp3在制备肿瘤细胞调控剂中的应用
CN115869339A (zh) * 2022-10-31 2023-03-31 中山大学附属第一医院 铜螯合剂与ampk激活剂联合用于制备肿瘤治疗药物的应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Arctigenin improves lipid metabolism by regulating AMP-activated protein kinase and downstream signaling pathways;Yuzhou Song等;Journal of Cellular Biochemistry;20190319;第120卷(第8期);第13275-13288页 *
Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of the key molecules involved in pancreatic carcinogenesis;Kotoe Kashiwaya等;Cancer Science;20090215;第100卷(第3期);第457-464页 *
Neuroprotective effects of olanzapine against rotenone-induced toxicity in PC12 cells Acta Pharmacologica Sinica;Ya-jie Xiong等;Acta Pharmacologica Sinica;20200302;第41卷;第508–515页 *
木鳖子对羟基桂皮醛通过调控cAMP-RhoA-MAPK途径诱导食管鳞状细胞癌分化作用研究;马鸣;中国博士学位论文全文数据库;20170815(第08期);第22-144页 *
脑缺血Akt和MAPK磷酸酶负性调节c-Jun N端激酶信号通路;朱建熹等;现代生物医学进展;20110630;第11卷(第11期);第2018-2021页 *

Also Published As

Publication number Publication date
CN116794325A (zh) 2023-09-22
WO2024254941A1 (zh) 2024-12-19

Similar Documents

Publication Publication Date Title
Li et al. The protein phosphatase 1 complex is a direct target of AKT that links insulin signaling to hepatic glycogen deposition
Langin et al. Importance of TNFα and neutral lipases in human adipose tissue lipolysis
Suizu et al. The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt
CN104232644B (zh) 一种特异抑制XOR基因表达的siRNA及其应用
Gu et al. PI3K signaling and miRNA expression during the response of quiescent human fibroblasts to distinct proliferative stimuli
Gao et al. PKCζ phosphorylates SIRT6 to mediate fatty acid β-oxidation in colon cancer cells
Zhai et al. Drug-induced premature senescence model in human dental follicle stem cells
Wang et al. microRNA‐135a protects against myocardial ischemia‐reperfusion injury in rats by targeting protein tyrosine phosphatase 1B
Mao et al. MicroRNA-19b mediates lung epithelial-mesenchymal transition via phosphatidylinositol-3, 4, 5-trisphosphate 3-phosphatase in response to mechanical stretch
Valentino et al. Evidence of myomiR regulation of the pentose phosphate pathway during mechanical load‐induced hypertrophy
CN116794325B (zh) 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用
Voelkl et al. SGK1-sensitive regulation of cyclin-dependent kinase inhibitor 1B (p27) in cardiomyocyte hypertrophy
Li et al. Increased sensitivity of DNA damage response-deficient cells to stimulated microgravity-induced DNA lesions
Ding et al. The role of H3K9me2‐regulated base excision repair genes in the repair of DNA damage induced by arsenic in HaCaT cells and the effects of Ginkgo biloba extract intervention
CN108079315B (zh) FBP aldolase在制备激活AMPK的药物中的用途
Rahm et al. Differential regulation of KCa2. 1 (KCNN1) K+ channel expression by histone deacetylases in atrial fibrillation with concomitant heart failure
Schmitt et al. ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells
CN117025623A (zh) SmMYCL1基因及其在提高丹参中丹酚酸含量中的应用
Zhong et al. TGF-β secreted by cancer cells-platelets interaction activates cancer metastasis potential by inducing metabolic reprogramming and bioenergetic adaptation
Liu et al. NDUFA9 and its crotonylation modification promote browning of white adipocytes by activating mitochondrial function in mice
Lee et al. Relative expression levels rather than specific activity plays the major role in determining in vivo AKT isoform substrate specificity
Gao et al. [Retracted] MicroRNA‐29a‐3p Regulates SH‐SY5Y Cell Proliferation and Neurite Growth through Interaction with PTEN‐PI3K/AKT/mTOR Signaling Pathway
CN103695421B (zh) 一种特异抑制p21基因表达的siRNA及其应用
CN101912617B (zh) Mg53基因在治疗胰岛素抵抗和ⅱ型糖尿病及其相关病症中的应用
Liu et al. Carbachol-induced signaling through Thr696-phosphorylation of myosin phosphatase-targeting subunit 1 (MYPT1) in rat bladder smooth muscle cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant